



Edmonton Research Park, 9407-20 Ave, Edmonton, AB T6N 1E5 (780)448-1400

## OFFICERS AND DIRECTORS

**Dr. Donald B. Rix**, M.D, Chairman  
**Dr. Madi R. Madiyalakan**, Ph.D, CEO and Director  
**Mr. Ian McConnan**, F.C.A., Director  
**Dr. Bin Huang**, Ph.D, MBA, Director  
**Mr. Thomas Woo**, M.Sc, Vice President, Product Development  
**Mr. Pierre Vermette**, C.A., Chief Financial Officer

## TRADING INFORMATION

<b>Fiscal Year End</b>	January 31
<b>Listing</b>	TSX Venture
<b>Trading Symbol</b>	QPT
<b>Share Capital Issued</b>	61,570,913
<b>Fully diluted</b>	72,040,913
<b>Year Founded</b>	1996
<b>Year Listed</b>	1999

## NEWS HIGHLIGHT

July 10, 2007 [Quest PharmaTech Engages AMC Technologies Corp. for Development of Home Use, Light Delivery Device for Hair Removal Application with SL017](#)

May 23, 2007 [Quest PharmaTech and Alberta Research Council form strategic alliance to develop alternate method to manufacture raw material for SonoLight Technology based products](#)

May 14, 2007 [Quest PharmaTech and Paramount BioSciences Sign Exclusive Multinational License Agreement to Develop and Commercialize SonoLight Technology for Dermatology Applications](#)

May 10, 2007 [Quest PharmaTech announces second equity investment by KMH Co. Ltd. in connection with Strategic Business Alliance to Distribute Cosmetic Hair Removal Product in Asia](#)

May 2, 2007 [Quest PharmaTech's Prostate Cancer Program Update](#)

January 9, 2007 [Quest Pharmatech Initiates a Fifty Patient Pivotal Clinical Trial for Cosmetic Hair Removal Application](#)

December 5, 2006 [Quest Pharmatech Strengthens its Patent Protection for SonoLight Technology](#)

## Overview

Quest PharmaTech is an Alberta-based, publicly traded biotechnology company committed to build shareholder value through discovery, development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and skin diseases, based on its SonoLight Technology platform.

## Proprietary Technology

The patented SonoLight Technology is based on a unique non-toxic family of photosensitizing and sonosensitizing, small molecular weight compounds called Hypocrellin, isolated from a parasitic fungus that grows on bamboo trees in China. Quest is developing these compounds as drugs, as well as developing novel means of activating and delivering them to target tissues. Quest's products are expected to offer high selectivity and efficacy with minimal side effects.

## Promising Products

The Company's lead product, SL017, is a topical formulation indicated for dermatology applications. The utility of SL017 has already been demonstrated for hair removal applications in a Phase I clinical trial. The Company has initiated a eighty patient Phase I/II pivotal clinical trial for the same indication. Use of SL017 with a light-based hair removal device is likely to overcome some of the limitations associated with the light treatment alone. In addition, SL017 is currently undergoing a Canadian Phase I clinical trial for Actinic Keratosis and is also being evaluated for acne treatment in a pig model.

A second product from the SonoLight platform, SL052, is an injectable formulation that is in late-stage pre-clinical development for prostate cancer treatment. SL052 will be delivered directly to the prostate by a unique delivery system thereby maximizing drug uptake and minimizing side effects. The animal studies done so far at the Cross Cancer Institute in Edmonton, Alberta indicate that SL052 has the potential to destroy cancerous tumors on the prostate while limiting collateral damage to healthy tissue. Complete shut down of metabolic activity at the tumor site is observed 24 hours post light treatment. Using the canine prostate model, it is shown that treatment of the prostate gland can cause complete glandular tissue ablation within the intact capsule. Quest plans to initiate a Phase I clinical trial for PDT treatment of prostate cancer during early 2008.

## Partnership

Quest has signed an exclusive multinational license agreement with Paramount Biosciences to develop and market SL017 and other HB derivatives for dermatology applications. Paramount is responsible for all development and clinical costs associated with the program. Quest retains the Canadian rights; and can receive milestones payments and royalty from product sales.

Quest also has an agreement with a Korean company (KMH Co. Ltd) to market SL017 in Asia for hair removal applications.

## Business Strategy

Expedite the commercialization of SL017 for hair removal applications. Advance the Corporation's two proprietary drugs into and through early stage clinical trials. Enter into strategic partnership with established companies to commercialize the products, which will also be the primary source of funds for the Company during product development.